Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Viz.ai's recent partnership with Sanofi and Regeneron Pharmaceuticals (NasdaqGS:REGN) brings AI technology to aid in the management of COPD patients, enhancing the healthcare process. Throughout ...

Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical ...

Today's health tech news covers Regeneron's new health tech deals, fundraisers from Cohere, Sprinter, Akido, and Commure's legal trouble.

Amazon is using AI to become more efficient and drive productivity. The company has already begun to see some solid operating leverage, but more should be on its way. These AI initiatives should ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Together, Viz.ai, Sanofi, and Regeneron aim to maximize patient impact, particularly for patients who stand to benefit most from improved follow-up and care.

Only 25% of AI initiatives have delivered expected return on investment (ROI), over the past three years, according to a new report from IBM, which surveyed 2,000 CEOs around the world during the ...